セレギリン
セレギリン（L-デプレニル）は、**うつ病**や**不安**などの純粋に感情的な原因による行動障害の治療に認可されたモノアミン酸化酵素阻害薬です。多動、分離不安、全般性恐怖症、非社交的行動などの治療において、行動療法と併用されることがよくあります。 これらの感情障害は通常、摂食、飲水、自己刺激行動、睡眠、探索行動の変化、恐怖や苛立ちに関連する攻撃性、および身体的障害（頻脈、感情的排尿など）を特徴とします。 > **臨床のポイント:** セレギリンは、特に不安や社会的引きこもりを伴う**犬の認知機能障害（CCD）**に強く適応され、高齢猫の認知機能低下の兆候の治療にも使用できます。特徴として、徐々に用量を減らす必要がなく、突然治療を中止することができます。
作用機序: Selegiline modifies the concentration of monoaminergic neurotransmitters, especially **phenylethylamine** and **dopamine**, by selectively inhibiting the activity of **Type-B monoamine oxidase (MAO-B)**, the enzyme that normally breaks down these chemicals. MAO-B inhibition → decreased breakdown of dopamine → increased dopamine concentrations in the CNS. It also appears to possess **neuroprotective properties**.
動物種別の用量
- Behavioural disorders and cognitive dysfunction · 0.5-1 mg/kg · PO · q24h · minimum of 2 months · Treatment can be stopped suddenly without gradual dose reduction.
- Cognitive decline in older cats · 1 mg/kg · PO · q24h · Not specified · Treatment can be stopped suddenly without gradual dose reduction.
用量は獣医療従事者向けの臨床リファレンスです。必ず最新の添付文書と個々の患者で確認してください。
投与経路
禁忌
- Known sensitivity to selegiline
- Lactating bitches (acts on prolactin secretion)
- Pregnant bitches
有害事象
- No specific adverse reactions are listed in the monograph
- Clinical Pearl: May occasionally cause mild gastrointestinal upset, restlessness, or lethargy
薬物相互作用
- Alpha-2 antagonists · Should not be administered concurrently or within 24 hours before/after use · major
- Pethidine · Contraindicated concurrent use · major
- Ephedrine · Contraindicated concurrent use · major
- Amitraz · Potential MAOI interaction; contraindicated · major
- Phenothiazines · Contraindicated concurrent use · major
- Morphine · Potentiates the effect of morphine · moderate
- Metronidazole · Potential interaction exists · minor
- Prednisolone · Potential interaction exists · minor
- Trimethoprim · Potential interaction exists · minor
- Tricyclic antidepressants (amitriptyline, doxepin, clomipramine) · Do not use selegiline for at least 2-3 weeks after TCA use · major
- Fluoxetine · Do not use selegiline for at least 6 weeks after long-term fluoxetine use · major
モニタリング
- Improvement in behavioural signs (anxiety, phobias, social withdrawal)
- Improvement in cognitive function (disorientation, sleep-wake cycle alterations)
- Adverse drug interactions if other medications are introduced
過量投与
No specific overdose information is provided in the monograph. **Clinical Pearl:** Overdoses of MAOIs can lead to signs of serotonin syndrome or excessive dopaminergic stimulation, including hyperthermia, tachycardia, tremors, and agitation. Treatment is supportive.
VetSheet の薬剤リファレンスは、獣医療従事者向けの臨床意思決定支援を目的としており、専門的判断やメーカーの最新添付文書に代わるものではありません。